• 1
    Twerenbold R, Jaffe A, Reichlin T, Reiter M, Mueller C. High-sensitive troponin T measurements: what do we gain and what are the challenges? Eur Heart J 2012; 33: 57986.
  • 2
    Omland T, de Lemos JA, Sabatine MS et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009; 361: 253847.
  • 3
    Latini R, Masson S, Anand IS et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116: 12429.
  • 4
    Masson S, Anand I, Favero C et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 2012; 125: 2808.
  • 5
    Otsuka T, Kawada T, Ibuki C, Seino Y. Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middle-aged men without overt cardiovascular disease. Am Heart J 2010; 159: 9728.
  • 6
    de Lemos JA, Drazner MH, Omland T et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 250312.
  • 7
    Saunders JT, Nambi V, de Lemos JA et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis risk in communities study. Circulation 2011; 123: 136776.
  • 8
    Leistner DM, Klotsche J, Pieper L et al. Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention. Clin Chem 2012; 58: 2008.
  • 9
    Wallace TW, Abdullah SM, Drazner MH et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113: 195865.
  • 10
    Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo study. J Am Coll Cardiol 2008; 52: 4509.
  • 11
    White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol 2011; 57: 24068.
  • 12
    Agarwal S, Thohan V, Shlipak MG et al. Association between Cystatin C and MRI measures of left ventricular structure and function: multi-ethnic study of atherosclerosis. Int J Nephrol 2011; 2011: 153868.
  • 13
    Eggers KM, Lind L, Ahlström H et al. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J 2008; 29: 22528.
  • 14
    Mureddu GF, Agabiti N, Rizzello V et al. Prevalence of asymptomatic left ventricular dysfunction and heart failure in the elderly (PREDICTOR) –A population-based study in Central Italy. Eur J Heart Fail 2012; 14: 71829.
  • 15
    Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 35867.
  • 16
    de Simone G, Devereux RB, Roman MJ et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23: 144451.
  • 17
    Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79108.
  • 18
    Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 54: 4108.
  • 19
    de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93: 25965.
  • 20
    Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 2006; 47: 5006.
  • 21
    Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194202.
  • 22
    Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391479.
  • 23
    Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010; 56: 25461.
  • 24
    Collinson PO, Heung YM, Gaze D et al. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin Chem 2012; 58: 21925.
  • 25
    Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322: 15616.
  • 26
    Andrén B, Lind L, Hedenstierna G, Lithell H. Left ventricular hypertrophy and geometry in a population sample of elderly males. Eur Heart J 1996; 17: 18007.
  • 27
    Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general population. The Tromsø Study. Eur Heart J 1999; 20: 42938.
  • 28
    Schussheim AE, Devereux RB, de Simone G, Borer JS, Herrold EM, Laragh JH. Usefulness of subnormal midwall fractional shortening in predicting left ventricular exercise dysfunction in asymptomatic patients with systemic hypertension. Am J Cardiol 1997; 79: 10704.
  • 29
    Wachtell K, Gerdts E, Palmieri V et al. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan intervention for endpoint reduction study. J Hypertens 2010; 28: 15416.
  • 30
    Cioffi G, Giorda CB, Chinali M et al. Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. Eur J Cardiovasc Prev Rehabil 2012; 19: 93543.
  • 31
    Clerico A, Fortunato A, Ripoli A, Prontera C, Zucchelli GC, Emdin M. Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations. Clin Chem Lab Med 2008; 46: 8048.
  • 32
    Luchner A, Bröckel U, Muscholl M et al. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. Cardiovasc Res 2002; 53: 7207.
  • 33
    Eggers KM, Lindahl B, Venge P, Lind L. B-type natriuretic peptides and their relation to cardiovascular structure and function in a population-based sample of subjects aged 70 years. Am J Cardiol 2009; 103: 10328.
  • 34
    de Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the cardiovascular health study. Eur Heart J 2008; 29: 7417.
  • 35
    Vasan RS, Benjamin EJ, Larson MG et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002; 288: 12529.
  • 36
    Goetze JP, Mogelvang R, Maage L et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006; 27: 300410.
  • 37
    de Lemos JA, McGuire DK, Khera A et al. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas heart study. Am Heart J 2009; 157: 74653e2
  • 38
    Costello-Boerrigter LC, Boerrigter G, Redfield MM et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 34553.